Edition:
United Kingdom

NanoCarrier Co Ltd (4571.T)

4571.T on Tokyo Stock Exchange

399JPY
16 Nov 2018
Change (% chg)

¥-3 (-0.75%)
Prev Close
¥402
Open
¥399
Day's High
¥409
Day's Low
¥397
Volume
291,100
Avg. Vol
403,970
52-wk High
¥1,337
52-wk Low
¥386

Latest Key Developments (Source: Significant Developments)

NanoCarrier signs exclusive agreement for global study on new approach of using NC-6004 to treat head and neck cancer
Friday, 20 Jul 2018 

July 20(Reuters) - NanoCarrier Co Ltd <4571.T>:Says NanoCarrier entered into a license and collaborative agreement with Orient Europharma Co Ltd <<<4120.TWO>>>(OEP), for co-development of NC-6004 with a new immunotherapy combination drug.This clinical approach will be developed at a global level in regions including United States, Europe and Asian countries(excluding Japan) for head and neck cancer patients building upon the basic agreement dated May 15, 2018.Under the terms of agreement, NanoCarrier grants OEP an exclusive license to develop NC-6004 globally for head and neck cancer, and NanoCarrier will receive a total of $8 million clinical milestone payments.  Full Article

NanoCarrier says basic agreement on international joint development of NC-6004 to treat head and neck cancer
Tuesday, 15 May 2018 

May 15 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says it entered into an agreement with the NC-6004 out-licensee, Orient Europharma Co Ltd <<<4120.TWO>>>, aimed at the Asian region, to integrate clinical development of NC-6004 for the treatment of head and neck cancer .Says two entities will conclude a basic agreement for additional licensing and joint development of NC-6004 in regions such as Europe and the United States.  Full Article

NanoCarrier signs license preferential negotiating rights agreement with AccuRna
Monday, 4 Dec 2017 

Dec 4 (Reuters) - NanoCarrier Co Ltd <4571.T> ::Says it and AccuRna Inc entered into a preferential negotiating rights agreement on exclusive right to license of drug development based on co's gene delivery technology.Co will get payment from AccuRna according to the agreement.Co also plans to inject capital into AccuRna Inc .  Full Article

VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Nanocarrier Co Ltd <4571.T>:VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan.Vascular Biogenics Ltd - ‍Nanocarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world​.Vascular - Pursuant to agreement, VBLT to supply nanocarrier with VB-111.Vascular - Nanocarrier will be responsible for all regulatory, other clinical activities necessary for commercialization of VB-111 in Japan.Vascular - VBLT receives up-front payment of $15 million & is entitled to receive greater than $100 million in development & commercial milestone payments​.Vascular Biogenics Ltd - ‍VBLT will also receive tiered royalties on net sales in high-teens​.Vascular Biogenics Ltd - ‍Other terms of agreement not disclosed​.  Full Article

Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan.Under terms of the agreement, VBL Therapeutics will supply the co with VB-111, and the co will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan.Says VBL Therapeutics will receive up-front payment of $15 million, development and commercial milestone payments and tiered royalties on net sales from the co.  Full Article

NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:* Says it and NanoCarrier Co., Ltd <4571.T> conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines .* Under this agreement, Nanocarrier and JCR will integrate the unique technologies and knowledge of both companies, and aim to develop an innovative drug effectively delivered to the brain .  Full Article